Mologen AG has confirmed plans to start a Phase 2 study of its lead compound, MGN1703, in non-small cell lung cancer having shown evidence earlier this year of improved progression free survival of the same drug in colorectal cancer. ---Subscribe to MedNous to access this article--- Clinical Research Company News
